Please login to the form below

Not currently logged in
Email:
Password:

Combination treatment

This page shows the latest Combination treatment news and features for those working in and with pharma, biotech and healthcare.

Janssen’s EGFR-targeting treatment regimen shows early benefit in lung cancer

Janssen’s EGFR-targeting treatment regimen shows early benefit in lung cancer

The CHRYSALIS study investigators assessed the efficacy of the combination treatment using overall response rate (ORR) markers, as well as clinical benefit rate, duration of response and the safety profile of ... In a group of 45 patients who had

Latest news

More from news
Approximately 0 fully matching, plus 274 partially matching documents found.

Latest Intelligence

  • As COVID-19 takes over the world, biopharma fights back As COVID-19 takes over the world, biopharma fights back

    A combination HIV treatment: AbbVie’s Kaletra. In an unprecedented move, AbbVie has suspended its patents on its combination HIV drug Kaletra, after it was identified as having potential against ... The combination drug was first included in Chinese

  • Deal Watch April 2016 Deal Watch April 2016

    Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... 85 . Dong A (SK). Tobira (US). Cross license. Evogliptin

  • Pharma deals in April 2015 Pharma deals in April 2015

    No deal terms were disclosed. The initial development plan will look at the combination therapy as a potential treatment for NHL.  . ... The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid.

  • Pharma deals during July 2014 Pharma deals during July 2014

    Underscoring its strategy in focusing the business in the core areas, in July Baxter also announced the acquisition of AesRx, a private US company developing a phase II stage prophylactic treatment ... The acquisition of Almirall's respiratory business

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    And again, matching drugs that work well together will be crucial going forward: “Combination treatment will be a critical component; how best to put these drugs together with other checkpoint inhibitors, ... This includes people with NSCLC who have a

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Oncosec

    body.  OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; ... Results from recently completed

  • Marketing strategy in complex environments

    The last few years have seen influential scientific advances, resulting in subtle shifts in how pharma tackles disease treatment. ... The treatment of aggressive diseases often benefits very noticeably from combination therapy, especially when involving

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics